Neurotrophic Keratitis Treatment Market By Therapy Type (Prescription Growth Factor Therapy, Peptide and Pipeline Therapies, Supportive Ocular Surface Therapies, Surgical and Procedural Interventions), By Disease Stage (Stage 1, Stage 2, Stage 3), By End User (Hospitals, Specialty Eye Clinics, Cornea Treatment Centers, Ambulatory Surgical Centers), By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Neurotrophic Keratitis Treatment Market Gains Value from Orphan Drug Access, Corneal-Healing Evidence, and Pipeline Pressure on Oxervate

The Global Neurotrophic Keratitis Treatment Market was valued at USD 826 million in 2025 and is projected to reach USD 1.40 billion by 2032, growing at a CAGR of 7.8%, according to Strategic Market Research.

 

The Neurotrophic Keratitis Treatment Market is a rare ophthalmology category with one approved prescription growth-factor therapy, heavy dependence on supportive procedures, and a pipeline trying to reduce treatment burden. Revenue is concentrated in patients with persistent epithelial defects, corneal ulceration, severe epithelial breakdown, poor visual outcomes, and limited response to lubrication, serum tears, amniotic membrane, contact lenses, or surgical protection.

 

Oxervate, or cenegermin-bkbj, anchors the approved drug segment. The product established recombinant human nerve growth factor as a regulated treatment route for neurotrophic keratitis, but the regimen remains demanding: one drop six times daily for eight weeks. New entrants are therefore competing less on disease awareness and more on practical treatment gaps, including earlier-stage intervention, simpler dosing, lower handling burden, sustained local nerve-growth-factor expression, peptide-based repair, and lower-cost corneal-healing alternatives.

 

Treatment Demand and Diagnosed Patient Pool

Neurotrophic keratitis has orphan-market economics, but prevalence estimates vary sharply by data source. The FDA’s 2018 statistical review cited the manufacturer’s estimate of 50,800 U.S. patients with neurotrophic keratitis. Moderate and severe Stage 2/3 disease represented roughly one-third of cases, or about 16,900 patients. That narrower Stage 2/3 pool is more relevant for premium therapy than the full disease estimate because these patients are more likely to have persistent epithelial defects, ulcers, corneal thinning, or vision-threatening complications.

The American Academy of Ophthalmology IRIS Registry identified 27,483 patients and 31,915 affected eyes between 2013 and 2018. Average six-year prevalence was 21.34 cases per 100,000 registry patients, mean age at diagnosis was 68 years, and 58.9% of patients were female. Herpetic keratitis and diabetes were the most common associated conditions, giving manufacturers and clinicians clear case-finding channels through cornea specialists, retina and diabetes-linked eye care, antiviral-treated patients, and post-surgical ophthalmology follow-up.

Claims activity suggests improving recognition after the Oxervate era began. Krystal Biotech’s 2025 annual filing stated that estimated U.S. neurotrophic keratitis claims rose from 31,000 patients in 2020 to 68,000 patients in 2024. The increase reflects stronger diagnosis capture, coding, specialist awareness, and referral activity rather than a proven doubling of underlying disease incidence. For suppliers, better capture of already existing patients is as important as true epidemiological expansion.

Europe remains an orphan-designation market. EMA’s orphan assessment estimated that neurotrophic keratitis affects fewer than 5 in 10,000 people, meeting the EU rarity threshold. German estimates based on a tertiary referral center placed annual incidence around 1–3 per 100,000 and prevalence around 2–5 per 100,000, although referral-center extrapolations tend to miss milder community cases and overrepresent advanced corneal disease.

 

Stage 2 and Stage 3 Patients Carry Most Treatment Value

Treatment spending rises when patients move beyond early epithelial damage. Stage 1 patients often receive preservative-free lubricants, punctal occlusion, medication review, serum or platelet-based tears, and closer monitoring. Stage 2 and Stage 3 patients create stronger commercial demand because persistent epithelial defects, corneal ulcers, stromal melting, perforation risk, and vision loss push care toward Oxervate, amniotic membrane, therapeutic contact lenses, tarsorrhaphy, corneal gluing, keratoplasty, and neurotization in selected cases.

A Kaiser Permanente Northern California cohort of 354 eyes in 322 patients showed the late-recognition problem clearly. At presentation, 37.3% of eyes were Stage 1, 32.5% were Stage 2, and 30.2% were Stage 3. Nearly two-thirds were already Stage 2 or Stage 3, and 47.5% had baseline vision worse than 20/100. Late-stage presentation keeps procedure use high and gives drug developers room to position earlier intervention before corneal damage becomes difficult to reverse.

Etiology also shapes the treatment funnel. In the Kaiser cohort, herpetic causes accounted for 34.9%, diabetes for 12.4%, ocular surgery for 10.4%, and central nervous system causes for 9.0%. Herpetic disease and diabetes are especially important because they represent large, identifiable patient pools already engaged with ophthalmology or chronic disease care. Better corneal sensitivity testing in these groups could expand treated cases without relying on broad public awareness campaigns.

 

Oxervate Defines the Approved Drug Standard

Oxervate remains the approved benchmark for prescription therapy. The FDA label lists cenegermin-bkbj as recombinant human nerve growth factor indicated for neurotrophic keratitis, with a concentration of 0.002%, or 20 mcg/mL. The approved schedule requires one drop in the affected eye six times per day at two-hour intervals for eight weeks. A full course can reach 336 administrations per affected eye, before adding storage, vial preparation, timing with other drops, caregiver support, and payer documentation.

Pivotal trial results give Oxervate a strong evidence position. In the FDA label, complete corneal healing at Week 8 was 65.2% versus 16.7% for vehicle in NGF0214 and 72.0% versus 33.3% in NGF0212. Treatment differences of 48.6 percentage points and 38.7 percentage points remain the reference standard for pipeline assets. New drugs must compete against complete epithelial healing, not only improvement in ocular surface appearance or symptom scores.

Tolerability and administration burden still influence real-world use. The Oxervate label reports adverse reactions such as eye pain, ocular hyperemia, eye inflammation, and increased lacrimation. Dompé’s prescribing materials report eye pain after instillation in about 16% of treated patients. In a rare disease with intensive dosing, completion support, patient training, specialty pharmacy handling, and payer authorization can affect uptake almost as much as physician willingness to prescribe.

 

Supportive and Procedural Care Remain Embedded in the Market

Cornea specialists still rely heavily on supportive and procedural products because many patients present with advanced epithelial damage or mixed ocular surface disease. Amniotic membrane, punctal plugs, bandage contact lenses, scleral lenses, serum tears, prophylactic antibiotics, antivirals, tarsorrhaphy, corneal gluing, and keratoplasty form the day-to-day treatment infrastructure around neurotrophic keratitis.

A 2025 Saudi tertiary-eye-hospital cohort showed how procedure-heavy real-world care remains. Among 94 eyes from 80 patients, 74% were Stage 2 and 20% were Stage 3. Preservative-free artificial tears were used in 98.9% of eyes, autologous serum tears in 60.6%, and therapeutic corneal or scleral contact lenses in 51.1%. Surgical procedures were frequent, led by amniotic membrane transplantation, tarsorrhaphy, and corneal gluing.

Severe outcomes in the same cohort explain why drug and procedure demand often overlap rather than substitute for one another. Corneal scarring occurred in 90.4% of eyes, corneal neovascularization in 56.4%, corneal perforation in 12.8%, and secondary bacterial keratitis in 17.0%. Severe visual impairment was present in 78.2% at presentation and 38.2% after treatment. Advanced presentation keeps procedural revenue high and gives newer drugs a clear target: earlier healing before scarring, thinning, or perforation creates irreversible visual damage.

 

Diagnosis Capture Remains a Commercial Constraint

Neurotrophic keratitis often lacks the pain signal that normally drives eye-care visits. In the Saudi cohort, only 11.9% of patients reported eye pain, while 88.1% had reduced vision and 20.2% had no symptoms. Patients can therefore reach Stage 2 or Stage 3 before seeking care or receiving the correct diagnosis. Corneal sensitivity testing, persistent epithelial defect protocols, and referral from diabetes, herpetic keratitis, and post-surgical care pathways are practical demand drivers for advanced therapy.

Expert consensus has also made treatment pathways more usable for clinicians. An 11-member modified-Delphi panel reached agreement across roughly 94% of rated scenarios and supported stage-based use of lubrication, punctal occlusion, serum or platelet-based drops, cenegermin, amniotic membrane, therapeutic lenses, tarsorrhaphy, tissue adhesive, and corneal neurotization. Clearer stage-based decision-making helps payers and clinicians distinguish routine ocular surface care from advanced neurotrophic keratitis treatment.

 

Pipeline Focus: Earlier Treatment and Lower Dosing Burden

Pipeline activity is targeting the weak points of current care rather than building another general dry-eye category. Developers are focusing on earlier-stage disease, complete epithelial healing, treatment durability, lower administration burden, local growth-factor expression, and cost-effective repair.

Lacripep is the most visible earlier-stage peptide program. TearSolutions announced in June 2026 that Lacripep received FDA Orphan Drug and Fast Track designations and that first patients were dosed in a Phase 2 trial for neurotrophic keratitis. The randomized, vehicle-controlled study plans to enroll approximately 54 subjects with Stage 1 disease. Lacripep is a synthetic peptide derived from lacritin, a human tear protein. Earlier-stage positioning gives the asset a different role from late epithelial-defect rescue therapy, provided it can show meaningful prevention of progression or measurable corneal repair.

KB801 is the most differentiated platform program. Krystal Biotech describes KB801 as an HSV-1-based eye-drop vector designed to deliver transgenes to corneal epithelial cells for sustained local nerve-growth-factor expression. EMERALD-1 is a randomized, double-masked, placebo-controlled registrational study expected to enroll approximately 60 adults with Stage 2 or Stage 3 neurotrophic keratitis. Local NGF production could challenge Oxervate’s externally administered recombinant protein model if the trial shows durable healing with a lower daily dosing burden.

RGN-259 carries more uncertainty after mixed late-stage results. HLB Therapeutics reported that the European SEER-3 Phase 3 study of RGN-259, a thymosin beta-4-based eye drop, did not meet the primary endpoint of complete corneal healing. The company continued the U.S. program, but the European result raises the evidence bar for non-NGF corneal-healing candidates. Future adoption will depend on whether RGN-259 can deliver a clearer healing signal in a controlled setting.

STSP-0902 and BRM424 add mid-stage optionality. STSP-0902 is being evaluated in a Phase 2 double-blind, placebo-controlled study in Stage 2 or Stage 3 disease, with planned enrollment of 48 patients across three dose groups. BRM424 is being studied in a small Phase 2 trial with estimated enrollment of 12 patients. Smaller programs may attract attention if they offer easier dosing, lower cost, or a healing profile strong enough to justify development against Oxervate.

 

Topical Insulin Adds a Low-Cost Pressure Point

Topical insulin has become relevant because cornea practices continue to look for lower-cost healing options. Reviews describe insulin eye drops as a promising approach for neurotrophic keratitis and other ocular surface disorders, although commercially standardized products are not yet broadly available. Compounded insulin therefore sits outside the approved branded market but still influences value expectations.

Premium products must compete with pragmatic clinic behavior. Cornea specialists may consider compounded or autologous options when branded therapy is difficult to access, when payer approval is delayed, or when patients cannot manage intensive schedules. Stronger branded adoption will require evidence on complete healing, durability, reduced procedure use, fewer perforations, better visual outcomes, or simpler administration.

 

Pediatric and Surgical Niches Add Specialist Demand

Pediatric neurotrophic keratitis is smaller in volume but clinically important in specialist centers. Childhood disease is more often congenital or inherited, while adult disease is more often acquired through herpetic infection, diabetes, surgery, or neurologic injury. Pediatric cases carry additional risk because corneal opacity can interfere with visual development and cause amblyopia.

Corneal neurotization remains a specialized surgical route for severe or recurrent disease. The procedure transfers healthy donor nerve tissue to restore corneal sensation and trophic support. Bilateral disease can require indirect techniques using sural nerve grafts. Neurotization does not compete with routine eye-drop therapy at scale, but it gives advanced centers another option for patients with severe denervation and repeated epithelial breakdown.

 

Competitive and Access Dynamics

Oxervate holds first-mover advantage through FDA approval, orphan positioning, randomized healing data, and established specialist awareness. Its main vulnerabilities are not weak efficacy but treatment intensity, storage and handling requirements, payer friction, and eye-pain tolerability. New drug developers need practical differentiation, not only a new mechanism.

Dompé remains the benchmark supplier through Oxervate. TearSolutions is trying to move treatment earlier through Lacripep. Krystal Biotech is trying to reduce dosing burden through local NGF expression with KB801. HLB Therapeutics must overcome the uncertainty created by SEER-3. STSP-0902 and BRM424 need clearer evidence before they can shift prescribing behavior or attract broader partnering interest.

Procedural and supportive-care suppliers retain strong positions because advanced neurotrophic keratitis often requires physical protection of the ocular surface. Amniotic membrane products, serum tears, punctal plugs, therapeutic contact lenses, tarsorrhaphy, and corneal gluing remain important even when drug therapy is available. Advanced disease keeps the market multi-modal rather than purely pharmaceutical.

 

North America and U.S. Market Behavior

North America leads the commercial market because the U.S. has an approved therapy, high specialty-drug reimbursement potential, strong cornea-specialist infrastructure, large registry visibility, and active clinical development. IRIS Registry data, rising claims estimates, TearSolutions’ Phase 2 initiation, and Krystal’s registrational KB801 program all point to the U.S. as the most important evidence-generation and launch market.

U.S. uptake will depend on diagnosis capture and access execution. Many patients are still identified late, and specialty therapy requires documentation of disease stage, failed prior care, epithelial defect status, and payer authorization. Practices that already manage herpetic keratitis, diabetic eye disease, post-surgical complications, and persistent epithelial defects are better positioned to identify eligible patients.

Europe remains important through orphan-drug pathways, Oxervate access, and corneal-healing trials, but reimbursement scrutiny is likely to remain higher than in the U.S. Products with lower dosing burden, stronger durability, or reduced procedure use may have better payer arguments than products offering another intensive topical regimen.

Asia-Pacific is gaining visibility through clinical development and specialist evidence. Chinese and Korean programs, including STSP-0902 and RGN-259-related activity, show regional participation in corneal-healing innovation. Adoption will depend on reimbursement depth, cornea-specialist concentration, local manufacturing, and price positioning against imported biologic therapy.

 

Market Outlook

Growth in the Neurotrophic Keratitis Treatment Market will come from earlier diagnosis, wider corneal sensitivity testing, stronger referral pathways, and new therapies that reduce the burden of the current Oxervate regimen. The category will not behave like a broad dry-eye market. Patient volume is limited, but Stage 2 and Stage 3 disease create high treatment intensity through prescription therapy, procedures, repeated monitoring, and surgical rescue.

Oxervate should remain the approved benchmark because its pivotal trials delivered strong complete-healing results and its regulatory position is clear. Competitive pressure will build around products that treat earlier disease, reduce dosing frequency, improve treatment completion, lower cost, or produce durable epithelial healing without repeated procedural intervention. Lacripep, KB801, RGN-259, STSP-0902, BRM424, topical insulin research, and corneal neurotization each address a different weakness in current care.

The most useful indicators for market tracking are diagnosed NK claims, Stage 2/3 share, Week-8 complete corneal healing, recurrence after healing, treatment completion, procedure use, corneal perforation, visual outcomes, payer coverage, and daily dosing burden. Suppliers that reduce epithelial failure, avoid surgical rescue, and simplify long-term cornea care will have the strongest position in this rare but high-need ophthalmology market.

 

Neurotrophic Keratitis Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 826 Million
Revenue Forecast in 2032	USD 1.40 Billion
Overall Growth Rate	CAGR of 7.8% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Therapy Type, By Disease Stage, By End User, By Geography
By Therapy Type	Prescription Growth Factor Therapy, Peptide and Pipeline Therapies, Supportive Ocular Surface Therapies, Surgical and Procedural Interventions
By Disease Stage	Stage 1 Neurotrophic Keratitis, Stage 2 Neurotrophic Keratitis, Stage 3 Neurotrophic Keratitis
By End User	Hospitals, Specialty Eye Clinics, Cornea Treatment Centers, Ambulatory Surgical Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising diagnosis of neurotrophic keratitis Increasing adoption of regenerative corneal therapies Orphan-drug development activity
Customization Option	Available upon request